Advertisement

Impact of overall corticosteroid exposure during chemoradiotherapy on lymphopenia and survival of glioblastoma patients

  • Caressa Y. Hui
  • Soumon Rudra
  • Sirui Ma
  • Jian L. Campian
  • Jiayi HuangEmail author
Clinical Study

Abstract

Purpose

Corticosteroids are commonly used to alleviate symptoms from cerebral vasogenic edema in glioblastoma (GBM) patients. This study evaluated the impact of overall corticosteroid exposure during chemoradiotherapy (CRT) on acute severe lymphopenia (ASL) and survival outcomes of GBM patients.

Methods

GBM patients treated with CRT from 2007 to 2016 were retrospectively analyzed. Overall corticosteroid exposure was estimated as the average daily dexamethasone dose during 6 weeks of CRT. ASL was defined as grade 3 or higher lymphopenia within 3 months of starting CRT. ASL rates, overall survival (OS), and progression-free survival (PFS) were analyzed using Kaplan–Meier method. Multivariable analysis (MVA) was performed using logistic and Cox regression to identify independent predictors of ASL and survival outcomes, respectively.

Results

Of the 319 eligible patients, the median daily dexamethasone use was 2 mg/day. The high-dose dexamethasone cohort (> 2 mg/day) had significantly higher ASL and worse OS than the low-dose dexamethasone cohort: 3-month ASL of 43.7% versus 19.8% (p < 0.003) and median OS of 12.6 months versus 17.9 months (p < 0.001), respectively. On MVA, higher dexamethasone use was independently associated with higher ASL and worse OS, but not worse PFS. A subset analysis of patients with gross-total resection found that higher dexamethasone use was significantly associated with ASL, but not OS.

Conclusion

Increased corticosteroid use among GBM patients during CRT appears to be an independent risk factor for developing subsequent ASL. Its apparent association with worse OS may be influenced by other confounding factors and would need to be validated through prospective investigations.

Keywords

Glioblastoma Corticosteroids Lymphopenia Chemoradiotherapy 

Notes

Acknowledgements

The authors would like to acknowledge Dan Mullen and Sandra Fergus for their tremendous support in data management and acquisition of radiation dosimetric data.

Compliance with ethical standards

Conflict of interest

J.H. reports research support from Pfizer and Cantex, personal fees from Viewray, outside the submitted work. J.L.C reports research support from NeoImmuneTech Inc. and Incyte Corporation, outside the submitted work. The remaining authors declare no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was waived for this study after evaluation of methodology by Institutional Review Board.

Supplementary material

11060_2019_3146_MOESM1_ESM.docx (39 kb)
Supplementary material 1 (DOCX 39 KB)

References

  1. 1.
    Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492–507CrossRefGoogle Scholar
  2. 2.
    Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG (2010) Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol 12(6):520–527CrossRefGoogle Scholar
  3. 3.
    Stupp R, Mason W, Bent M, van den Weller M, Fisher B, Taphoorn M et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for globlastoma. N Engl J Med 352:987–996CrossRefGoogle Scholar
  4. 4.
    Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S et al (2011) Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17(16):5473–5480CrossRefGoogle Scholar
  5. 5.
    Mendez JS, Govindan A, Leong J, Gao F, Huang J, Campian JL (2016) Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. J Neurooncol 127(2):329–335CrossRefGoogle Scholar
  6. 6.
    Rudra S, Hui C, Rao YJ, Samson P, Lin AJ, Chang X et al (2018) Effect of radiation treatment volume reduction on lymphopenia in patients receiving chemoradiotherapy for glioblastoma. Int J Radiat Oncol 101(1):217–225CrossRefGoogle Scholar
  7. 7.
    Huang J, Dewees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S et al (2015) Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys 92(5):1000–1007.  https://doi.org/10.1016/j.ijrobp.2015.04.005 CrossRefGoogle Scholar
  8. 8.
    Lin AJ, Campian JL, Hui C, Rudra S, Rao YJ, Thotala D et al (2018) Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neuro-Oncol 136(2):403–411CrossRefGoogle Scholar
  9. 9.
    Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24(9):1459CrossRefGoogle Scholar
  10. 10.
    Chitadze G, Flüh C, Quabius ES, Freitag-Wolf S, Peters C, Lettau M et al (2017) In-depth immunophenotyping of patients with glioblastoma multiforme: impact of steroid treatment. Oncoimmunology 6(11):e1358839CrossRefGoogle Scholar
  11. 11.
    Wong ET, Lok E, Gautam S, Swanson KD (2015) Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. Br J Cancer 113(2):232–241CrossRefGoogle Scholar
  12. 12.
    Pitter KL, Tamagno I, Alikhanyan K, Hosni-Ahmed A, Pattwell SS, Donnola S et al (2016) Corticosteroids compromise survival in glioblastoma. Brain 139(5):1458–1471CrossRefGoogle Scholar
  13. 13.
    Deasy JO, Blanco AI, Clark VH (2003) CERR: A computational environment for radiotherapy research. Med Phys 30(5):979–985.  https://doi.org/10.1118/1.1568978 CrossRefGoogle Scholar
  14. 14.
    Hughes MA, Parisi M, Grossman S, Kleinberg L (2005) Primary brain tumors treated with steroids and radiotherapy: Low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 62(5):1423–1426CrossRefGoogle Scholar
  15. 15.
    Sampson JH, Maus MV, June CH (2017) Immunotherapy for brain tumors. J Clin Oncol 35(21):2450–2456CrossRefGoogle Scholar
  16. 16.
    Shields LBE, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S et al (2015) Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients. Radiat Oncol 10(1):222CrossRefGoogle Scholar
  17. 17.
    Sur P, Sribnick EA, Patel SJ, Ray SK, Banik NL (2005) Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells. Glia 50(2):160–167CrossRefGoogle Scholar
  18. 18.
    Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370(8):699–708CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Caressa Y. Hui
    • 1
  • Soumon Rudra
    • 2
  • Sirui Ma
    • 2
  • Jian L. Campian
    • 3
  • Jiayi Huang
    • 2
    Email author
  1. 1.Saint Louis University School of MedicineSaint LouisUSA
  2. 2.Department of Radiation OncologyWashington University School of MedicineSt. LouisUSA
  3. 3.Division of OncologyWashington University School of MedicineSt. LouisUSA

Personalised recommendations